Постпрандиальная гликемия: возможность надежного и эффективного контроля
- Авторы: Мкртумян А.М1, Бирюкова Е.В1, Давыдов А.Л1, Маркина Н.В1
-
Учреждения:
- ГОУ ВПО МГМСУ Росздрава
- Выпуск: Том 10, № 9 (2008)
- Страницы: 19-23
- Раздел: Статьи
- URL: https://bakhtiniada.ru/2075-1753/article/view/92743
- ID: 92743
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаОб авторах
А. М Мкртумян
ГОУ ВПО МГМСУ Росздрава
Е. В Бирюкова
ГОУ ВПО МГМСУ Росздрава
А. Л Давыдов
ГОУ ВПО МГМСУ Росздрава
Н. В Маркина
ГОУ ВПО МГМСУ Росздрава
Список литературы
- Adeghate E, Schatiner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci 2006; 1084 (1): 1–29.
- Kimmel B, Inzucchi E.M. Oral Agents for Type 2 Diabetes: An Update. Clin Diab 2005; 23 (2): 64–76.
- Shim W.S, Kim S.K, Kim H.J. Decremental of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur J Endocrinol 2006; 155 (4): 615–22.
- Esposito K, Giugliano D, Nappo F et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110 (2): 214–9.
- Leiter L.A, Ceriello A, Davidson J.A et al. Postprandial glucose regulation: new data and new implications. Clin Ther 2005; 27(Suppl. B): S42–56.
- Ubink-Veltman L.J, Bilo H.J, Groenier K.H et al. Prevalens, incidence and mortality of type 2 diabetes mellitus revisited:a prospective populacion - based study in the Netterlands (ZODIAC-1). Eur J Epidemiol 2003; 18 (8): 793–800.
- Culy C.R, Jarvis B. Repaglinide:a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001; 61 (11): 1625–60.
- Home P.D. Postprandial hyperglycaemia: mechanisms and importance. Diabetes Obesity Metab 2000; 2 (Suppl. 1): S7–S11.
- Ruigomez A, Rodrigues L.A. Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor. Eur J Epidemiol 1998; 14 (15): 439–45.
- De Fronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281–303.
- Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22–9.
- Guay D.R. Repaglinide,a novel short - acting hypoglycaemia agent for type 2 diabetes mellitus. Pharmacotherapy 1998; 18: 1195–204.
- Henquin J.C, Garrino M.G, Nenquien M. Stimulation of insulin release by benzoic acid derivatives related to the non - sulphonylurea moiety glibenclamide: structural requirements and cellular mechanisms. Eur J Pharmacol 1987; 8: 11–6.
- Owens D.R. Repaglinide: prandial glucose regulator:a new class of oral antidiabetic drugs. Diabet Med 15 (Suppl. 4): S28–36.
- Johansen O.E, Birkeland K.I. Defining the role of repaglinide in the management of type 2 diabetes mellitus:a review. Am J Cardiovasc Drugs 2007; 7 (5): 319–35.
- Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide:a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? Int J Obes Relat Metab Disord 2000; 24 (Suppl. 3): S21–31.
- Moses R.G. Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes:a reanalysis of earlier data in terms of current targets. Clin Ther 2008; 30 (3): 552–4.
Дополнительные файлы
